4.6 Review

Synthetic Lethality in Ovarian Cancer

期刊

MOLECULAR CANCER THERAPEUTICS
卷 20, 期 11, 页码 2117-2128

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1535-7163.MCT-21-0500

关键词

-

类别

资金

  1. Eunice Kennedy Shriver National Institute of Child Health & Human Development [K12 HD000849]
  2. GOG Foundation, Reproductive Scientist Development Program
  3. Robert and Deborah First Family Fund
  4. Saltonstall Research Fund
  5. Potter Research Fund
  6. Sperling Family Fund Fellowship
  7. Bach Underwood Fund
  8. Minnesota Ovarian Cancer Alliance
  9. Honorable Tina Brozman Foundation
  10. Massachusetts Life Sciences Center Bits to Bytes Program
  11. Mighty Moose Foundation

向作者/读者索取更多资源

This article summarizes key information on overcoming chemoresistance in ovarian cancer using synthetic lethality strategies, including the biological rationale and clinical evaluation of targeting BRCA-PARP synthetic lethality. In addition, it also discusses how to apply synthetic lethality strategies in non-BRCA mutant cancers, along with the combination of PARP inhibitors and other methods to target ovarian cancer.
Ovarian cancers include several distinct malignancies which differ with respect to clinicopathologic features and prognosis. High-grade serous cancer is the most common histologic subtype and accounts for most ovarian cancer-related deaths. High-grade serous ovarian cancer (HGSOC) is treated with surgery and platinum-based chemotherapy, but most patients relapse and succumb to chemoresistant disease. The genetic concept of synthetic lethality, in which the synergy of mutations in multiple genes results in cell death, provides a framework to design novel therapeutic approaches to overcome chemoresistance in ovarian cancer. Recent progress in understanding the genomic architecture and hereditary drivers of ovarian cancer has shown potential for synthetic lethality strategies designed around homologous DNA repair. Clinical trials have validated high response rates for PARP inhibitors in patients with BRCA1 or BRCA2 mutations. Here we discuss the biological rationale behind targeting BRCA-PARP synthetic lethality based on genetic context in ovarian cancer and how this approach is being assessed in the clinic. Applying the concept of synthetic lethality to target non-BRCA-mutant cancers is an ongoing challenge, and we discuss novel approaches to target ovarian cancer using synthetic lethality in combination with and beyond PARP inhibitors. This review will also describe obstacles for synthetic lethality in ovarian cancer and new opportunities to develop potent targeted drugs for patients with ovarian cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据